HBsAg阳性心脏死亡器官捐献供肝的选择性使用及对肝移植预后的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (975 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the selective use of donor livers after cardiac death (DCD) with hepatitis B surface antigen (HBsAg) positive and its effect on the prognosis of liver transplantation.Methods With informed consent, liver transplantation recipients of HBsAg positive cardiac dead organs donated by our hospital were studied, where bidirectional cohort study was used. Intraoperative zero hepatic biopsy specimens were obtained from each of these cases, and the secondary hepatic biopsy was performed on patients with a lifespan of more than 1 year. The status of hepatitis B virus, liver function biochemical index, coagulation function and patient survival after liver transplantation were analyzed. Liver fibrosis and inflammation changes before and after surgery were compared.Results The 1-year, 3-year and 5-year survival rates of liver transplant recipients were 86.8%, 75.5% and 62.3% respectively. Serum HBsAg of each patient was positive during the follow-up, but HBV-DNA was well controlled. the liver function of the survivors was good at 1 year after operation. The degree of inflammation of the liver perforating tissue was significantly reduced during postoperative follow-up (1.98±0.67 vs 1.65±0.79, P=0.02), while the degree of fibrosis was not significantly changed (0.83±0.58 vs 0.68±0.61, P=0.31). The degree of zero-point liver tissue inflammation was not related to the liver function at 1 year after surgery, while the degree of liver tissue fibrosis was positively correlated with total bilirubin (TBIL), International Normalized Ratio (INR) and Model for End-Stage Liver Disease (MELD score) at 1 year after surgery. The correlation coefficients were 0.56 (P=0.04), 0.59 (P=0.02) and 0.68 (P=0.01), respectively. In this study, 20 patients died during the follow-up, including 3 patients with primary hepatic reactive power, 2 patients with F2 stage (2/12), 1 patient with F3 stage (1/3), 11 patients with tumor recurrence, 5 patients with infection and 1 patient with gastrointestinal hemorrhage.Conclusions For HBsAg positive DCD donor livers, zero hepatic histopathological examination is of great significance in guiding the rational use of donor livers, F0 stage and F1 stage can be used normally, F2 stage is suitable for patients with mild disease, and F3 stage should not be used. With careful selection of donor receptors and proper anti-hepatitis measures, donor livers can be fully utilized and good prognosis can be obtained.

Key words： liver transplantation HBsAg positive donor selective use prognosis

Received: 02 December 2018

ZTFLH:

R617

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIAO Hua
	CHEN Xinguo
	ZHU Xiongwei
	WU Fengdong
	WANG Weiwei
	DOU Gufeng
	NIU Yujian

Cite this article:

XIAO Hua,CHEN Xinguo,ZHU Xiongwei等. Selective use of HBsAg-positive DCD donor livers and impact on prognosis of liver transplantation[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(3): 244-248.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2019/V30/I3/244

[1]	郑树森, 俞军, 张武. 肝移植在中国的发展现状[J]. 临床肝胆病杂志, 2014, 30(1): 2-4.
[2]	王颖, 陈新国, 王文妍,等. 3次原位肝移植术后7年再次行同种异体肾移植术后的健康教育1例[J]. 武警医学, 2016, 27(1): 103-105.
[3]	刘荣强, 张英才, 姚嘉,等. 乙型肝炎表面抗原阳性供肝肝移植的临床疗效分析[J]. 器官移植, 2017, 8(6): 450-454.
[4]	解曼, 饶伟. 乙型肝炎核心抗体阳性供者在肝移植中的研究进展[J]. 中华器官移植杂志, 2014, 35(9): 570-573.
[5]	Niu Y, Chen X, Feng L, et al. Anti-HBc-positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts [J]. Clin Res Hepatol Gastroenterol, 2014, 38(4):475-480.
[6]	Lai J C, O’Leary J G, Trotter J, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study[J]. Liver Transpl, 2012, 18(5): 532-538.
[7]	Wang W, Niu Y, Yue Y, et al. Selection of liver graft from HCV-positive donor and prognosis of liver transplant recipients[J]. Int J ClinExp Pathol, 2016, 9(10):10817-10823.
[8]	陈新国, 沈中阳, 牛玉坚, 等. HBsAg阳性供者供肝用于乙型肝炎合并超UCSF标准肝癌肝移植20例[J]. 中华器官移植杂志, 2013, 34(9): 528-531.
[9]	中华人民共和国国务院. 人体器官移植条例[J]. 中华移植杂志(电子版), 2007, 1(1): 61-63.
[10]	China Organ Donation Committee. China guide of donation after cardiac death [J]. China Organ Transplant, 2010, 31(7): 436-437.
[11]	王乐天, 沈中阳, 牛玉坚,等. 核苷类似物联合乙肝免疫球蛋白预防肝移植后乙肝病毒再感染的远期效果[J]. 武警医学, 2010, 21(11): 939-940.
[12]	Li Z, Hu Z, Xiang J, et al. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database [J]. Liver Transpl, 2014, 20(1): 35-45.
[13]	Jiao Z, Zhang Y, Han L, et al. Four-year follow-up of two chronic hepatitis B recipients of hepatitis B surface antigen-positive cadaveric liver grafts from asymptomatic carriers[J]. Hepatol Res, 2011, 41(3): 846-852.
[14]	Jeng L B, Thorat A, Yang H R, et al. Successful use of hepatitis B surface antigen-positive liver grafts an effective source for donor organs in endemic areas: a single-center experience [J]. Ann Transplant, 2015, 20(23): 103-111.
[15]	Li Zhiwei, Hu Zhenhua. Use of hepatitis B surface antigen-positiveGrafts in liver transplantation: a matched analysis of the US national database[J]. Liver Transpl, 2014, 20(1): 35-45
[16]	余松峰, 俞军, 张微, 等. HBsAg阳性供肝在肝移植中应用的单中心经验总结[C].//2015浙江省肿瘤外科学术年会暨首届钱江国际肿瘤外科高峰论坛论文集. 浙江大学医学院附属第一医院/浙江省第一医院, 2015: 79-80.
[17]	唐缨, 牛宁宁. 肝移植超声新技术应用进展[J].器官移植, 2015, 6(1): 19-21.
[18]	孟海鹏, 雷建勇. 活体肝移植供体安全性的研究[J]. 中国普外基础与临床杂志, 2015, 22 (12): 1428-1433.
[19]	高永艳, 梁萍. 肝纤维化程度无创技术评估进展[J]. 武警医学, 2016, 27(5):513-516.
[20]	沈中阳. 中国肝移植乙型肝炎防治指南( 2016版) [J]. 临床肝胆杂, 2017, 33(2): 213 -220.